Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
As part of the ApoEurope Project, apolipoprotein E (apo E) common polymorphism and serum concentration were determined in 489 Alzheimer's disease patients and 429 controls. Patients and controls were recruited through nine centres in eight European countries. Age, sex ratios and education levels of both case and control populations were similar, although discrete differences appeared between centres. The prevalence of the ε4 allele was higher in Alzheimer's disease than in controls (increased by 140%), while serum apo E concentration was lower by 11.2% (p<0.001). In addition, serum total cholesterol and triglyceride concentrations were lower in Alzheimer's disease (p<0.001), while that of apo AI was not affected. The decrease in serum apo E concentration was not accounted for by the ε4 allele, age or gender, suggesting that apo E concentration might represent an additional risk factor for Alzheimer's disease, complementary and independent of the ε4 allele. Further analysis will be aimed at determining whether the quantitative link between apo E concentration and Alzheimer's disease occurs through the effect of apo E genotype on lipid parameters or by other mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“The allelic frequency of ε4 was markedly increased in AD cases across eight of the nine populations, as first described by the Roses group in 1993 (5, 7, 37).”
BackgroundApolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347 · cited 2×
“The E protein is produced and secreted in the brain and found in senile plaques and neurofibrillary tangles and may be involved in the pathogenesis of AD (8, 9).”
BackgroundSelf-citationAllelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcı́a, M. A., Aldudo, J., Vázquez, J., & Valdivieso, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01543-3 · Cited by 229
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., & Corbo, R. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00889-1 · Cited by 83 · cited 3×
“(23) observed a dual effect of apo E genotype: plasma apo E concentration increased in ε2, while it decreased in ε3/3 or ε3/4 cases.”
Background
Cited by
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Biological markers for therapeutic trials in Alzheimer’s disease
Frank, R. A., Galasko, D., Hampel, H., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 252
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034078 · Cited by 214
“Similarly the literature on the relationship between APOE e4 allele and plasma ApoE levels is limited and controversial with some studies showing increased apoE protein levels in APOE e4 allele carriers [31,33,35], while other studies observe the opposite [29,30].”
ResultBlood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
Plasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156
Metadata
- Authors
- Siest, G., Bertrand, P., Qin, B., Herbeth, B., Serot, J.-M., Masana, L., Ribalta, J., Passmore, A. P., Evans, A., Ferrari, M., Franceschi, M., Shepherd, J., Cuchel, M., Beisiegel, U., Zuchowsky, K., Rukavina, A. S., Sertic, J., Stojanov, M., Kostic, V., Mitrevski, A., Petrova, V., Sass, C., Merched, A., Salonen, J. T., Tiret, L., Visvikis, S., & group, T. A.
- Venue
- cclm
- Publisher
- Walter de Gruyter GmbH
- Published
- 2000-08-21
- Volume
- 38
- Issue
- 8
- Pages
- 721-730
- ISSN
- 1434-6621 (ISSN-L)
- OpenAlex
- W1978219957
- Cited by
- 74
- References
- 7
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.